LEGEND BIOTECH CORP-ADR (LEGN) Stock Analyst Ratings
NASDAQ:LEGN • US52490G1022
19.75 USD
+1.63 (+9%)
At close: Feb 23, 2026
19.4636 USD
-0.29 (-1.45%)
After Hours: 2/23/2026, 8:00:03 PM
ChartMill assigns a Buy % Consensus number of 83% to LEGN. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 68.76. This target is 248.17% above the current price.
- LEGN was analyzed by 25 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about LEGN.
- In the previous month the buy percentage consensus was at a similar level.
- LEGN was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-04 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-22 | TD Cowen | Downgrade | Buy -> Hold |
| 2026-01-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-20 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-07 | Oppenheimer | Initiate | Outperform |
| 2025-12-17 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-12-12 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-08 | UBS | Maintains | Buy -> Buy |
| 2025-11-13 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-11-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-13 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-25 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-12 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-02 | UBS | Maintains | Buy -> Buy |
| 2025-05-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-22 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-17 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-03-12 | Guggenheim | Reiterate | Neutral -> Neutral |
| 2025-03-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
LEGEND BIOTECH CORP-ADR / LEGN FAQ
What is the price target for LEGN stock?
25 analysts have analysed LEGN and the average price target is 68.76 USD. This implies a price increase of 248.17% is expected in the next year compared to the current price of 19.75.
How do analysts rate LEGEND BIOTECH CORP-ADR (LEGN)?
The consensus rating for LEGEND BIOTECH CORP-ADR (LEGN) is 83.2 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed LEGEND BIOTECH CORP-ADR (LEGN)?
The number of analysts covering LEGEND BIOTECH CORP-ADR (LEGN) is 25.